fludarabine and bryostatin 1

fludarabine has been researched along with bryostatin 1 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's3 (60.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Al-Katib, AM; Beck, FW; Dutcher, BS; Hamdy, N; Limvarapuss, C; Mohammad, RM; Wall, NR1
Chen, JH; Grant, S; Kramer, LB; Rao, AS; Tang, L; Vrana, JA; Wang, Z1
Ahmad, I; Al-Katib, AM; Beck, FW; Liu, KZ; Mantsch, HH; Mohammad, RM; Wall, NR1
Cragg, L; Feldman, EJ; Grant, S; Roberts, JD; Smith, MR1
Carter, WH; Cragg, L; Feldman, EJ; Grant, S; Honeycutt, C; Millenson, MM; Murgo, AJ; Padavic-Shaller, K; Ramakrishnan, V; Roberts, JD; Roboz, GJ; Smith, MR; Thune, R1

Trials

2 trial(s) available for fludarabine and bryostatin 1

ArticleYear
Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.
    Clinical lymphoma, 2002, Volume: 3, Issue:3

    Topics: Antineoplastic Agents; Bryostatins; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Macrolides; Vidarabine

2002
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Oct-01, Volume: 12, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Macrolides; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate; Vidarabine

2006

Other Studies

3 other study(ies) available for fludarabine and bryostatin 1

ArticleYear
Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
    International journal of oncology, 1999, Volume: 14, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bryostatins; Cell Division; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Macrolides; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured; Vidarabine

1999
Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1.
    Leukemia, 1999, Volume: 13, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Bryostatins; Cell Differentiation; Cell Division; Drug Interactions; Drug Screening Assays, Antitumor; Humans; Lactones; Leukemia, Myelomonocytic, Acute; Macrolides; U937 Cells; Vidarabine

1999
Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.
    International journal of molecular medicine, 2000, Volume: 5, Issue:4

    Topics: Aged; Antineoplastic Agents; Biological Transport, Active; Bryostatins; Carrier Proteins; Cladribine; Deoxycytidine Kinase; Dipyridamole; Down-Regulation; Drug Resistance, Neoplasm; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Macrolides; Male; Membrane Proteins; Nucleoside Transport Proteins; Phosphorylation; Thioinosine; Tumor Cells, Cultured; Vidarabine

2000